Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study

INTRODUCTION: OnabotulinumtoxinA is approved in the USA for the prevention of headache in adults with chronic migraine, a debilitating neurologic disease characterized by headaches occurring on ≥ 15 days per month for > 3 months and including migraine features on ≥ 8 days per month. OBJECTIVE: Th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Saf
Hlavní autoři: Winner, Paul K., Blumenfeld, Andrew M., Eross, Eric J., Orejudos, Amelia C., Mirjah, Debbie L., Adams, Aubrey Manack, Brin, Mitchell F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2019
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647876/
https://ncbi.nlm.nih.gov/pubmed/31102144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-019-00824-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky